Acta Pharmaceutica Sinica B
|
2026, 16(1): 647-650
• Letters to the editor •
Rifamycin O as a novel CRBN ligand for targeted degradation of IKZF1/3 proteins in hematopoietic malignancies
Full
Liang Liao1,2, Qiang Wang1, Zhengyang Gao1, Jiayao Liu1, Yuxuan Tong1, Xin Chen1, Jin Zhu1, Jian Li1,3,4, Jinlian Wei1
Affiliations
1 State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China;
2 Department of Technology Transfer, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;
3 Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi 832003, China;
4 Key Laboratory of Tropical Biological Resources of Ministry of Education, College of Pharmacy, Hainan University, Haikou 570228, China
doi: 10.1016/j.apsb.2025.10.033
Outline
CRBN
/
Fluorescence polarization
/
Rifamycin O
/
Novel ligand
/
Hematopoietic malignancies
/
IKZF1/3
/
Molecular glue
/
Proteasomal degradation
Liang Liao, Qiang Wang, Zhengyang Gao, Jiayao Liu, Yuxuan Tong, Xin Chen, Jin Zhu, Jian Li, Jinlian Wei.
Rifamycin O as a novel CRBN ligand for targeted degradation of IKZF1/3 proteins in hematopoietic malignancies[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(1)
: 647
-650
.
DOI: 10.1016/j.apsb.2025.10.033
Year 2026 volume 16 Issue 1
PDF
7
4
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2025.10.033
- Receive Date:2025-01-27
- Online Date:2026-09-17